[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100639457":3},{"organization":4,"armGroups":7,"interventions":7,"overallOfficials":7,"centralContacts":7,"locations":8,"responsibleParty":43,"collaborators":47,"id":54,"slug":55,"hasResults":56,"nctId":57,"briefTitle":58,"officialTitle":59,"acronym":7,"eligibilityCriteria":60,"healthyVolunteers":56,"sex":61,"minAge":62,"maxAge":7,"enrollmentInfo":63,"targetDuration":66,"studyType":67,"phases":7,"briefSummary":68,"conditions":69,"keywords":7,"overallStatus":73,"whyStopped":7,"lastUpdateSubmitDate":74,"lastUpdatePostDateStruct":75,"startDateStruct":78,"completionDateStruct":80,"leadSponsor":82,"locationsCount":83},{"fullName":5,"class":6},"Stanford University","OTHER",null,[9,28],{"facility":10,"status":7,"city":11,"state":12,"zip":13,"country":14,"countryCode":15,"cosmosGeoPoint":16,"geoPoint":21,"contacts":22},"Stanford University Hypertension Center","Palo Alto","California","94304","United States","US",{"type":17,"coordinates":18},"Point",[19,20],-122.14302,37.44188,{"lat":20,"lon":19},[23],{"name":24,"role":25,"phone":26,"phoneExt":7,"email":27},"Joel Nicholus, MA","CONTACT","650-947-7025","nicholus@stanford.edu",{"facility":29,"status":7,"city":30,"state":31,"zip":32,"country":14,"countryCode":15,"cosmosGeoPoint":33,"geoPoint":37,"contacts":38},"Duke University Hospital","Durham","North Carolina","27710",{"type":17,"coordinates":34},[35,36],-78.89862,35.99403,{"lat":36,"lon":35},[39],{"name":40,"role":25,"phone":41,"phoneExt":7,"email":42},"Krista Camuglia, BSN","919-862-5967","krista.camuglia@duke.edu",{"type":44,"investigatorFullName":45,"investigatorTitle":46,"investigatorAffiliation":5,"oldNameTitle":7,"oldOrganization":7},"SPONSOR_INVESTIGATOR","Vivek Bhalla","Associate Professor of Medicine (Nephrology)",[48,51],{"name":49,"class":50},"Idorsia Pharmaceuticals Ltd.","INDUSTRY",{"name":52,"class":53},"Duke University Medical Center, Durham, NC","UNKNOWN","100639457","impact-htn-study-of-patients-with-hypertension-100639457",false,"NCT07579260","IMPACT-HTN Study of Patients With Hypertension","Prospective Early Patient Experience Initiative (IMPACT-HTN)","Inclusion Criteria:\n\n* Signed and dated informed consent form\n* Ability to answer survey questions and to report blood pressure reading monthly\n* Male and female participants; 18 years or older\n* Treated with at least 2 antihypertensive therapies of different pharmacological classes for at least 4 weeks before the screening visit\n* Mean Sitting Systolic Blood Pressure (SiSBP) greater or equal to 130 mmHg\n\nExclusion Criteria:\n\n* Confirmed severe hypertension (grade 3) defined as SiSBP greater than or equal to 180 mmHg and\u002For Sitting Diastolic Blood Pressure (SiDBP) greater than or equal to 110 mmHg\n* Clinically significant unstable cardiac disease at screening or in the past in the opinion of the investigator\n* Heart failure NYHA functional class III and IV or NT-proBNP \\> 500 pg\u002FmL\n* Severe renal insufficiency or eGFR \\\u003C 15 mL\u002Fmin\u002F1.73m2\n* Moderate to severe hepatic impairment (Child-Pugh B and C) or elevated aminotransferase (\\> 3 x ULN)","ALL","18 Years",{"count":64,"type":65},100,"ESTIMATED","97 Days","OBSERVATIONAL","An estimated 120 million people have high blood pressure (hypertension) in the US, of which approximately 10% have resistant hypertension. This study aims to enroll patients who continue to have hypertension while being treated with at least two medications. The study will follow patients for approximately 3 months and collect real-world information on changes in their health to identify an ideal patient profile that would benefit from 4th-line antihypertensive therapies, including, but not limited to, FDA-approved aprocitentan, renal denervation, mineralocorticoid receptor antagonists, etc.",[70,71,72],"Hypertension (HTN)","Hypertension","Blood Pressure, High","NOT_YET_RECRUITING","2026-06-24",{"date":76,"type":77},"2026-06-29","ACTUAL",{"date":79,"type":65},"2026-07-01",{"date":81,"type":65},"2027-04-01",{"name":45,"class":6},2]